Neurocrine Biosciences Yönetim

Yönetim kriter kontrolleri 4/4

Neurocrine Biosciences CEO'su Kyle Gano, Jan2011 tarihinde atandı, in görev süresi 13.83 yıldır. in toplam yıllık tazminatı $ 5.99M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.1% maaş ve 89.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.13% ine doğrudan sahiptir ve bu hisseler $ 16.69M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.9 yıl ve 9.1 yıldır.

Anahtar bilgiler

Kyle Gano

İcra Kurulu Başkanı

US$6.0m

Toplam tazminat

CEO maaş yüzdesi	10.1%
CEO görev süresi	13.8yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	6.9yrs
Yönetim Kurulu ortalama görev süresi	9.1yrs

Son yönetim güncellemeleri

Recent updates

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)

Oct 10

Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth

Jul 09

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

May 08

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Apr 27

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

Apr 25

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Mar 31

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

Feb 11

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Jan 07

Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Dec 11

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Sep 12

We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Jun 08

CEO Tazminat Analizi

Kyle Gano'un ücretlendirmesi Neurocrine Biosciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$386m
Jun 30 2024	n/a	n/a	US$339m
Mar 31 2024	n/a	n/a	US$370m
Dec 31 2023	US$6m	US$603k	US$250m
Sep 30 2023	n/a	n/a	US$191m
Jun 30 2023	n/a	n/a	US$176m
Mar 31 2023	n/a	n/a	US$64m
Dec 31 2022	US$5m	US$551k	US$155m
Sep 30 2022	n/a	n/a	US$58m
Jun 30 2022	n/a	n/a	US$12m
Mar 31 2022	n/a	n/a	US$71m
Dec 31 2021	US$6m	US$517k	US$90m
Sep 30 2021	n/a	n/a	US$445m
Jun 30 2021	n/a	n/a	US$365m
Mar 31 2021	n/a	n/a	US$402m
Dec 31 2020	US$7m	US$488k	US$407m
Sep 30 2020	n/a	n/a	US$93m
Jun 30 2020	n/a	n/a	US$205m
Mar 31 2020	n/a	n/a	US$177m
Dec 31 2019	US$5m	US$443k	US$37m
Sep 30 2019	n/a	n/a	US$21m
Jun 30 2019	n/a	n/a	US$18m
Mar 31 2019	n/a	n/a	-US$39m
Dec 31 2018	US$5m	US$403k	US$21m
Sep 30 2018	n/a	n/a	US$10m
Jun 30 2018	n/a	n/a	-US$52m
Mar 31 2018	n/a	n/a	-US$106m
Dec 31 2017	US$2m	US$375k	-US$143m

Tazminat ve Piyasa: Kyle 'nin toplam tazminatı ($USD 5.99M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 12.73M ).

Tazminat ve Kazançlar: Kyle 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Kyle Gano (51 yo)

13.8yrs

Görev süresi

US$5,990,215

Tazminat

Mr. Kyle W. Gano, Ph D., is CEO and Director at Neurocrine Biosciences, Inc since October 11, 2024. He was Chief Business Development and Strategy Officer at Neurocrine Biosciences, Inc. since 2020 until O...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kyle Gano	CEO & Director	13.8yrs	US$5.99m	0.13% $ 16.7m
Matthew Abernethy	Chief Financial Officer	7yrs	US$6.06m	0.031% $ 3.9m
Jude Onyia	Chief Scientific Officer	3yrs	US$7.22m	0.013% $ 1.6m
Eiry Roberts	Chief Medical Officer	6.8yrs	US$5.87m	0.031% $ 3.8m
Jane Sorensen	Head of Investor Relations	no data	Veri yok	Veri yok
Darin Lippoldt	Chief Legal Officer & Corporate Secretary	10.1yrs	US$4.72m	0.039% $ 4.9m
Julie Cooke	Chief Human Resources Officer	7.2yrs	Veri yok	0.018% $ 2.2m
Eric Benevich	Chief Commercial Officer	9.5yrs	US$5.81m	0.040% $ 5.0m
David Boyer	Chief Corporate Affairs Officer	5.2yrs	Veri yok	0.00037% $ 46.2k
Ingrid Delaet	Chief Regulatory Officer	2.1yrs	Veri yok	0.0025% $ 309.6k
Christopher O'Brien	Exclusive Consultant	6.8yrs	US$3.10m	Veri yok

6.9yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: NBIX 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kyle Gano	CEO & Director	less than a year	US$5.99m	0.13% $ 16.7m
Christine Poon	Independent Director	1.3yrs	US$813.45k	0% $ 0
Richard Pops	Independent Director	26.6yrs	US$492.04k	0.031% $ 3.9m
Stephen Sherwin	Independent Director	25.6yrs	US$479.54k	0.024% $ 3.0m
William Rastetter	Independent Chairman of the Board	14.8yrs	US$495.04k	0.037% $ 4.6m
Gary Lyons	Independent Director	31.8yrs	US$460.11k	0.12% $ 14.7m
George Morrow	Independent Director	9.1yrs	US$479.54k	0.0042% $ 518.0k
Kevin Gorman	Director	16.8yrs	US$15.75m	0.51% $ 63.4m
Shalini Sharp	Independent Director	4.8yrs	US$497.11k	0.00098% $ 122.3k
Leslie Norwalk	Independent Director	5.2yrs	US$475.11k	0.00098% $ 122.3k
Johanna Mercier	Independent Director	3.6yrs	US$467.61k	0.0021% $ 258.4k

9.1yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NBIX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.1 yıldır).

Neurocrine Biosciences Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Chief Medical Officer exercised options to buy US$903k worth of stock.

Chief Corporate Affairs Officer notifies of intention to sell stock

Chief Corporate Affairs Officer notifies of intention to sell stock

Independent Chairman of the Board recently sold US$2.1m worth of stock

Independent Director exercised options and sold US$1.2m worth of stock

Chief Human Resources Officer exercised options and sold US$1.2m worth of stock

Recent updates

Chief Medical Officer exercised options to buy US$903k worth of stock.

Neurocrine Biosciences, Inc. Presents New KINECT-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health with INGREZZA (Valbenazine) Capsules

Neurocrine Biosciences, Inc. Presents Breadth of Data Demonstrating Holistic Improvements over Time in Patients with Tardive Dyskinesia Following Treatment with INGREZZA (Valbenazine) Capsules

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Neurocrine Biosciences, Inc. (NasdaqGS:NBIX) announces an Equity Buyback for $300 million worth of its shares.

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)

Neurocrine Biosciences, Inc. to Report Q3, 2024 Results on Oct 30, 2024

The Play On Neurocrine Biosciences

Chief Corporate Affairs Officer notifies of intention to sell stock

Chief Corporate Affairs Officer notifies of intention to sell stock

Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

Investor sentiment deteriorates as stock falls 18%

Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data

Price target increased by 7.0% to US$172

Independent Chairman of the Board recently sold US$2.1m worth of stock

Independent Director exercised options and sold US$1.2m worth of stock

Chief Human Resources Officer exercised options and sold US$1.2m worth of stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Neurocrine Biosciences, Inc. Raises Sales Guidance for the Full Year of 2024

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Chief Financial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc. Launches INGreZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing

Neurocrine Biosciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth

Chief Human Resources Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH

Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Independent Director notifies of intention to sell stock

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis

Chief Financial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

Consensus EPS estimates fall by 12%

Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules

Insufficient new directors

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Chief Commercial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc., Annual General Meeting, May 22, 2024

Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Independent Director notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

CEO & Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024

Insider notifies of intention to sell stock

Neurocrine Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 07, 2024

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Insider notifies of intention to sell stock

Chief Human Resources Officer notifies of intention to sell stock

Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Insider notifies of intention to sell stock

Sosei Heptares’ Partner Neurocrine Biosciences Confirms Its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Reports Update on the Phase 2 Clinical Trial

Neurocrine Biosciences® Presents Ingrezza® (Valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated with Huntington's Disease Through Week 50 At Huntington Study Group 2023